<DOC>
	<DOCNO>NCT01449838</DOCNO>
	<brief_summary>This clinical study protocol single centre , randomize , double blind , placebo control , single repeat dose study investigate safety , tolerability pharmacokinetics intravenous dose Colistin Methanesulfonate Sodium ( CMS-Na ) healthy Japanese male subject . Eighteen subject receive CMS-Na 2.5mg/kg ( colistin activity 75,000 IU/kg ) placebo single dose twice daily 2.5 day intravenous infusion . Blood urine sample pharmacokinetics analysis take regular interval dose . Safety assess measurement vital sign , Echocardiogram ( ECGs ) , safety laboratory data , renal function review adverse event .</brief_summary>
	<brief_title>Phase I Study Colistin Methanesulfonate Sodium</brief_title>
	<detailed_description />
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>&lt; Inclusion Criteria &gt; A subject eligible inclusion study follow criterion apply : 1 . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . 2 . Japanese ethnic origin define born Japan , four ethnic Japanese grandparent , hold Japanese passport identity paper able speak Japanese . Subjects also live outside Japan le 10 year time screen . 3 . Male 20 55 year age inclusive , time signing informed consent . 4 . Subjects must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication completion followup visit . 5 . Body weight 50 kg ( inclusive ) BMI ( body mass index ) within range 18.5 25 kg/m2 inclusive . 6 . AST , ALT , alkaline phosphatase bilirubin le 1.5 ( inclusive ) xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 7 . Subjects clinically significant value CLcr , NAG beta2 microglobulin judged investigator . 8 . Average QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block take triplicate assessment screen . 9 . No clinically active relevant abnormality 12lead ECG screening . 10 . Nonsmokers ( never smoke smoking &gt; 6 month &lt; 10 pack year history [ Pack year = ( cigarette per day smoked/20 ) x number year smoke ] ) 11 . A signed date write informed consent obtain subject 12 . The subject capable give informed consent , include compliance requirement restriction list consent form 13 . Able complete study procedure plan treatment period . &lt; Exclusion Criteria &gt; A subject eligible inclusion study follow criterion apply : 1 . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates benzodiazepine . The detection drug legitimate medical use would necessarily exclusion study participation . 2 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . 3 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 4 . A positive test HIV antibody . 5 . History regular alcohol consumption within 3months study define : average weekly intake great 21 unit average daily intake great 3 unit . One unit equivalent 285 mL glass full strength beer 425 mL schooner light beer 1 ( 30 mL ) measure spirit 1 glass ( 100 mL ) wine ( NHMRC Guidelines [ NHMRC , 2001 ] ) 6 . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 7 . Exposure four new chemical entity within 12 month prior first dose day . 8 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . 9 . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . 10 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 11 . Unwillingness inability follow procedure outline protocol . 12 . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product prior screen . 13 . The subject know allergy hypersensitivity colistin derive component . 14 . Subject keep regulatory judicial order institution . 15 . Subject mentally legally incapacitate . 16 . The subject 's systolic blood pressure outside range 90140 mmHg diastolic blood pressure outside range 4590 mmHg . 17 . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . &lt; Other Eligibility Criteria Considerations &gt; To assess potential impact subject eligibility regard safety , investigator must refer Prescribing Information ( see Appendix 2 , 3 4 ) detail information regard warning , precaution , contraindication , adverse event , significant data pertain investigational product use study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>